What happened in the premarket for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock?

AREB Stock
AREB Stock

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), shares nosedived in the premarket ‎session today as it recorded down -33.49% to reach $61.47. There is no clear answer to why ‎this stock dropped todayother than “confused investors.” ‎

Get the hottest stocks to trade every day before the market ‎opens 100% ‎free. Click here now. 

‎The only significant piece of recent news directly affecting this stockwas that ARCT had ‎received approval from the Singapore Health Sciences Authority to initiate a Phase 2 clinical ‎study of its vaccine candidate ARCT-021. In addition to favorable Phase 1/2 results, this ‎study will build on preclinical data,supporting its efficacy.‎

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Read More

Steve Hughes, M.D., Chief Development Officer of Arcturus, said in a ‎statement that upon the basis of our promising Phase 1/2 results, we have decided to ‎advance ARCT-021 into a Phase 2 study. Based on those data and more, we believe our ‎technology can provide a highly effective yet differentiated clinical profile, including a ‎single-dose regimen.‎

Our Phase 2 study will enable us to select the optimal ARCT-021 vaccination ‎regimen for Phase 3 registration studies. We hope to have interim Phase 2 data in ‎early 2021 to provide the basis for our Phase 3 study, which is expected to be ‎initiated in Q2 2021, he added.‎


Please enter your comment!
Please enter your name here